journal article·2020-07-08Open access

An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced Immunotherapy

Jiyoon Bu, Ashita Nair, Mari Iida, Woo-jin Jeong, Michael J. Poellmann, Kara Mudd, Luke J. Kubiatowicz, Elizabeth W. Liu, Deric L. Wheeler, Seungpyo Hong

Nano Letters· Volume 20· Issue 7

Abstract

Upregulation of programmed death ligand 1 (PD-L1) allows cancer cells to evade antitumor immunity. Despite tremendous efforts in developing PD-1/PD-L1 immune checkpoint inhibitors (ICIs), clinical trials using such ICIs have shown inconsistent benefits. Here, we hypothesized that the ICI efficacy would be dictated by the binding strength of the inhibitor to the target proteins. To assess this, hyperbranched, multivalent poly(amidoamine) dendrimers were employed to prepare dendrimer-ICI conjugates (G7-aPD-L1). Binding kinetics measurements using SPR, BLI, and AFM revealed that G7-aPD-L1 exhibits significantly enhanced binding strength to PD-L1 proteins, compared to free aPD-L1. The binding avidity of G7-aPD-L1 was translated into in vitro efficiency and in vivo selectivity, as the conjugates improved the PD-L1 blockade effect and enhanced accumulation in tumor sites. Our results demonstrate that the dendrimer-mediated multivalent interaction substantially increases the binding avidity of the ICIs and thereby improves the antagonist effect, providing a novel platform for cancer immunotherapy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Cancer Immunotherapy and Biomarkers · Peptidase Inhibition and Analysis · Radiopharmaceutical Chemistry and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States

Department of Human Oncology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States

Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States

Yonsei Frontier Lab and Department of Pharmacy, Yonsei University, Seoul 03722, Republic of Korea

Funding

National Cancer Institute · National Institute of Dental and Craniofacial Research · Division of Materials Research

References (49)

Show source-provided references
1. 10.1016/j.semcancer.2005.07.00810.1016/j.semcancer.2005.07.008 ↗
2. 10.1002/anie.20171040710.1002/anie.201710407 ↗
3. 10.1146/annurev.immunol.26.021607.09033110.1146/annurev.immunol.26.021607.090331 ↗
4. 10.1167/iovs.07-160610.1167/iovs.07-1606 ↗
5. 10.1111/j.1399-0039.2006.00701.x10.1111/j.1399-0039.2006.00701.x ↗
6. Thalya B. · Discrete Contin. Dyn.-B · 2003 · 4 · 13510.3934/dcdsb.2004.4.135 ↗
7. 10.1038/s41551-018-0236-810.1038/s41551-018-0236-8 ↗
8. 10.1021/acsnano.8b0244610.1021/acsnano.8b02446 ↗
9. 10.1002/adfm.20170724910.1002/adfm.201707249 ↗
10. 10.1016/j.biomaterials.2018.04.03910.1016/j.biomaterials.2018.04.039 ↗
11. 10.1016/j.biomaterials.2016.03.00710.1016/j.biomaterials.2016.03.007 ↗
12. 10.1038/bjc.2014.55510.1038/bjc.2014.555 ↗
13. 10.1073/pnas.061153310410.1073/pnas.0611533104 ↗
14. 10.1038/s41416-018-0144-410.1038/s41416-018-0144-4 ↗
15. 10.1007/s00262-006-0266-z10.1007/s00262-006-0266-z ↗
16. 10.1158/1078-0432.CCR-08-160810.1158/1078-0432.CCR-08-1608 ↗
17. 10.1016/j.intimp.2018.06.00110.1016/j.intimp.2018.06.001 ↗
18. 10.1056/NEJMoa120069410.1056/NEJMoa1200694 ↗
19. Ventola C. L. · P & T: a peer-reviewed journal for formulary management · 2017 · 42 · 514
20. 10.1021/acsnano.6b0815210.1021/acsnano.6b08152 ↗
21. 10.1016/j.jtho.2018.04.01710.1016/j.jtho.2018.04.017 ↗
22. 10.1038/s41589-018-0161-x10.1038/s41589-018-0161-x ↗
23. 10.18632/oncotarget.869810.18632/oncotarget.8698 ↗
24. 10.1002/anie.20110550810.1002/anie.201105508 ↗
25. 10.2217/nnm-2018-008410.2217/nnm-2018-0084 ↗
26. 10.1186/s40580-018-0170-110.1186/s40580-018-0170-1 ↗
27. 10.1038/srep0944510.1038/srep09445 ↗
28. 10.1021/jacs.9b1016010.1021/jacs.9b10160 ↗
29. 10.1021/bc049801810.1021/bc0498018 ↗
30. 10.1021/la000035c10.1021/la000035c ↗
31. 10.1006/abio.2002.565210.1006/abio.2002.5652 ↗
32. Poellmann M. J. · Nano Lett. · 2020
33. 10.1021/la052087d10.1021/la052087d ↗
34. 10.1529/biophysj.105.08029110.1529/biophysj.105.080291 ↗
35. 10.1021/acs.jpcb.5b0102810.1021/acs.jpcb.5b01028 ↗
36. 10.1016/S0006-3495(97)78802-710.1016/S0006-3495(97)78802-7 ↗
37. 10.1074/jbc.M117.78601210.1074/jbc.M117.786012 ↗
38. 10.1158/2326-6066.CIR-13-012710.1158/2326-6066.CIR-13-0127 ↗
39. 10.7150/jca.2905210.7150/jca.29052 ↗
40. 10.1158/1078-0432.CCR-17-307810.1158/1078-0432.CCR-17-3078 ↗
41. 10.1021/acs.analchem.5b0276610.1021/acs.analchem.5b02766 ↗
42. 10.1016/j.bios.2020.11225010.1016/j.bios.2020.112250 ↗
43. 10.18632/oncotarget.723510.18632/oncotarget.7235 ↗
44. 10.1038/nature2364310.1038/nature23643 ↗
45. 10.1007/s00262-019-02386-w10.1007/s00262-019-02386-w ↗
46. 10.1021/nn500299p10.1021/nn500299p ↗
47. 10.1158/2326-6066.CIR-15-025210.1158/2326-6066.CIR-15-0252 ↗
48. 10.1016/j.jconrel.2014.05.00610.1016/j.jconrel.2014.05.006 ↗
49. 10.1111/jphp.1309810.1111/jphp.13098 ↗